<?xml version="1.0" encoding="UTF-8"?>
<jcr:root xmlns:jcr="http://www.jcp.org/jcr/1.0" xmlns:cq="http://www.day.com/jcr/cq/1.0" xmlns:mix="http://www.jcp.org/jcr/mix/1.0" xmlns:nt="http://www.jcp.org/jcr/nt/1.0" xmlns:sling="http://sling.apache.org/jcr/sling/1.0"
          jcr:primaryType="cq:Page">
  <jcr:content
    cq:template="/apps/wcm-io-samples/sample-app/templates/content/content"
    jcr:primaryType="cq:PageContent"
    jcr:title="Cyclopentolate"
    sling:resourceType="/apps/wcm-io-samples/sample-app/components/content/page/content">
    <content
      jcr:primaryType="nt:unstructured"
      sling:resourceType="wcm-io/wcm/parsys/components/parsys">
      <contentheadline
        jcr:primaryType="nt:unstructured"
        sling:resourceType="wcm-io-samples/sample-app/components/content/common/contentHeadline"
        headline="Cyclopentolate" />
      <contentrichtext
        jcr:primaryType="nt:unstructured"
        sling:resourceType="wcm-io-samples/sample-app/components/content/common/contentRichText"
        text="&lt;p&gt;[[Image:Cyclopentolate 1 percent Pupils.jpg|thumb|alt=Both eyes instilled with cyclopentolate 1%, causing both [[mydriasis]] and [[cycloplegia]]|[[Cycloplegia]] caused by Cyclopentolate 1% instilled into both eyes.]]
{{Drugbox
| Verifiedfields = changed
| verifiedrevid = 460110763
| IUPAC_name = 2-(dimethylamino)ethyl (1-hydroxycyclopentyl)(phenyl)acetate
| image = Cyclopentolate.png
| CASNo_Ref = {{cascite|correct|CAS}}
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 2802
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = I76F4SHP7J
| InChI = 1/C17H25NO3/c1-18(2)12-13-21-16(19)15(14-8-4-3-5-9-14)17(20)10-6-7-11-17/h3-5,8-9,15,20H,6-7,10-13H2,1-2H3
| InChIKey = SKYSRIRYMSLOIN-UHFFFAOYAZ
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C17H25NO3/c1-18(2)12-13-21-16(19)15(14-8-4-3-5-9-14)17(20)10-6-7-11-17/h3-5,8-9,15,20H,6-7,10-13H2,1-2H3
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = SKYSRIRYMSLOIN-UHFFFAOYSA-N
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 512-15-2
| ATC_prefix = S01
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 1200473
| ATC_suffix = FA04
| ATC_supplemental =
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB00979
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 4024
| PubChem = 2905
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D07759
|smiles = O=C(OCCN(C)C)C(c1ccccc1)C2(O)CCCC2
| C=17 | H=25 | N=1 | O=3
| molecular_weight = 291.385 g/mol
| bioavailability =
| protein_bound =
| metabolism =
| elimination_half-life =
| pregnancy_category = C
| legal_status =
| routes_of_administration = Topic
}}

&amp;apos;&amp;apos;&amp;apos;Cyclopentolate&amp;apos;&amp;apos;&amp;apos; is a medication commonly used during [[pediatric]] [[eye examination]]s that dilates the eye ([[mydriatic]]), prevents [[Accommodation (eye)|accommodation]] of the eye to different distances ([[cycloplegia|cycloplegic]]), and blocks specific receptors called [[Muscarinic acetylcholine receptor|muscarinic receptors]] ([[muscarinic antagonist]]).&amp;lt;ref&amp;gt;{{cite web|url=http://www.drugbank.ca/drugs/DB00979|title=Cyclopentolate|accessdate=June 15, 2012}}&amp;lt;/ref&amp;gt;  Cyclopentolate is also administered as an [[atropine]] substitute to reverse muscarinic and central nervous system effects of indirect [[cholinomimetic]] (anti-AChase) administration.

When used in eye drops in pediatric eye examinations, Cyclopentolate 0.5 percent and 1.0 percent is used to stop the eye focusing at near distance, enabling the [[ophthalmologist]], [[optometrist]], or [[orthoptist]] to obtain a more accurate reading of the focusing power of the eyes. Brand names include Cyclogyl, Cylate, &amp;amp; Pentolair.&amp;lt;ref&amp;gt;{{cite web|url=http://www.medicinenet.com/cyclopentolate_hydrochloride-eye_drops/article.htm|title=cyclopentolate hydrochloride solution - ophthalmic, Cyclogyl, Cylate, Pentolair|accessdate=June 15, 2012}}&amp;lt;/ref&amp;gt;

The drops take around 30-60 minutes to work and less than 24 hours to wear off (with patients advised not to drive a vehicle or operate machinery for the first 12 hours). The pupils become wider when Cyclopentolate is administered, making the eyes more sensitive to light. Close objects (and possibly distant objects) will also appear blurred.

Side effects to Cyclopentolate are rare, but can include effects such as disorientation, incoherent speech or visual disturbances during the 24-hour period that the drug has an effect. The side effects are more common in children.

== References ==
{{Reflist|refs
&amp;lt;ref name=vaughan&amp;gt;{{cite book|last=John P.Whitcher, Paul Riordan-Eva|title=Vaughan &amp;amp; Asbury&amp;apos;s general ophthalmology.|publisher=McGraw-Hill Medical|isbn=978-0071443142|page=63|edition=17th ed.}}&amp;lt;/ref&amp;gt;
}}

{{Mydriatics and cycloplegics}}
{{Cholinergics}}

[[Category:Ophthalmology drugs]]
[[Category:Amines]]
[[Category:Carboxylate esters]]
[[Category:Alcohols]]

{{pharmacology-stub}}&lt;/p&gt;" />
    </content>
  </jcr:content>
</jcr:root>
